Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis.

Curr Oncol · 2025 · PMC12468209 · PMID 41002563

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

20.2 months; unstratified HR 0.75, 95% CI 0.40–1.41), the serplulimab group had a favorable trend toward improved OS [ 54 ].

also in 957 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.